Business
Bionano Genomics Announces Launch of Its Rare Undiagnosed Genetic Disease (RUGD) Strategic Initiative Aimed at the 350 Million People Globally Living with a Rare Disease
Rare diseases affect more than 350 million people globallyIt is estimated that 1 in 15 people globally are affected by a rare diseaseEstimates are that 25
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Rare diseases affect more than 350 million people globallyIt is estimated that 1 in 15 people globally are affected by a rare diseaseEstimates are that 25 million Americans and 30 million in Europe are living with a rare disease More than 7,000 rare diseases have been identified to dateApproximately 80% of rare disease are believed to be caused by genetic factorsIt takes on average 7 seven years, with standard techniques, to obtain an accurate diagnosisEven after all these standard techniques, more than 50% of patients with rare diseases remain go undiagnosed SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the launch of its rare undiagnosed genetic disease (RUGD) strategic initiative in recognition of Rare Disease Day. There are many different causes of rare disease, but most are genetic and believed to be directly caused by changes in genes or chromosomes. In some cases, genetic changes that cause disease are passed from one generation to the next. In other cases, they occur randomly in a person who is the first in their family to be diagnosed. Karyotyping, fluorescent in situ hybridization (FISH), chromosomal microarray (CMA), targeted next-generation sequencing (NGS) and whole genome sequencing (WGS) are broadly used during the diagnostic odysseys associated with rare diseases and yet more than 50% of patients on average are left undiagnosed. The patients are left on a frustrating and stressful RUGD odysseys without answers. A major part of the solution is genome testing and research. Bionano offers a suite of solutions with OGM systems, genome analysis software and testing and laboratory services that may provide valuable answers for RUGD research. Today, Bionano is launching its RUGD initiative in an effort to help elevate the level of focus and dedication in translational and clinical research. Bionano’s RUGD initiative will include Bionano’s suite of product offerings, support for educational awareness, working towards development of research grants in this area and supporting professional societies with a shared mission of improving RUGD patient care and management, such as the...